Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Luminex Teams With Merck For Alzheimer’s Companion Diagnostic

This article was originally published in The Gray Sheet

Executive Summary

The assay will be used to support patient selection as part of Merck’s ongoing clinical trial program for the MK-8931 Alzheimer’s disease drug candidate.

You may also be interested in...



News Briefs: FDA Turns Down Wright’s Augment; Cook Resumes Zilver PTX Shipments; Luminex Restructures

Wright Medical receives not approvable letter for its Augment bone graft asking for another study. Judge rules against Zimmer in favor of Strkyer in patent case. Cook Medical has resolved the problems that triggered a December 2012 recall of its Zilver PTX peripheral stent. Luminex cuts staff, invests in molecular diagnostics efforts.

Merck Partners On Alzheimer’s Diagnostic With GE Healthcare

Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.

Approved Nearly 75 Years Ago, Bufferin NDA On Withdrawal Notice Due To Registration Lapse

Attention must be paid when withdrawal is for NDA approved in 1948 for brand synonymous with nonprescription pain relief, Bufferin. Even when FDA’s decision amounts to NDA database recordkeeping, withdrawal of application demands notice in US OTC space.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel